Urea Cycle Disorders Portfolio

About Medunik

Medunik USA, founded in 2014 and launched commercially in 2017, is a private, commercial-stage biopharmaceutical company specializing in providing orphan drugs for rare diseases in the United States. As a strategic subsidiary of Canada's Duchesnay Pharmaceutical Group, it leverages international partnerships to identify, secure U.S. approval for, and ensure the continuous supply of rare disease therapeutics. The company's mission centers on bridging treatment gaps for underserved patient populations, with an initial focus on hematology and urea cycle disorders, while adhering to high standards of compliance and ethical responsibility.

Therapeutic Areas